Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: A fatal attraction. Nat Rev Cancer 2011, 11: 411–425.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93: 247–257.

Article  PubMed  Google Scholar 

Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999, 353: 1695–1700.

Article  CAS  PubMed  Google Scholar 

Falk S, Dickenson AH. Pain and nociception: Mechanisms of cancer-induced bone pain. J Clin Oncol 2014, 32: 1647–1654.

Article  CAS  PubMed  Google Scholar 

Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002, 2: 201–209.

Article  CAS  PubMed  Google Scholar 

Goblirsch MJ, Zwolak P, Clohisy DR. Advances in understanding bone cancer pain. J Cell Biochem 2005, 96: 682–688.

Article  CAS  PubMed  Google Scholar 

Watkins LR, Milligan ED, Maier SF. Glial activation: A driving force for pathological pain. Trends Neurosci 2001, 24: 450–455.

Article  CAS  PubMed  Google Scholar 

Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science 2016, 354: 572–577.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch. Nat Rev Neurosci 2019, 20: 667–685.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni C, Chen L, Hua B, Han Z, Xu L, Zhou Q. Epigenetic mechanisms of bone cancer pain. Neuropharmacology 2024, 261: 110164.

Article  CAS  PubMed  Google Scholar 

Xu C, Wang Y, Ni C, Xu M, Yin C, He Q, et al. Histone modifications and Sp1 promote GPR160 expression in bone cancer pain within rodent models. EMBO Rep 2024, 25: 5429–5455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, Guan KL. Hippo signaling in embryogenesis and development. Trends Biochem Sci 2021, 46: 51–63.

Article  CAS  PubMed  Google Scholar 

Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev 2014, 94: 1287–1312.

Article  CAS  PubMed  Google Scholar 

Halder G, Johnson RL. Hippo signaling: Growth control and beyond. Development 2011, 138: 9–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen CG, Moroishi T, Guan KL. YAP and TAZ: A nexus for Hippo signaling and beyond. Trends Cell Biol 2015, 25: 499–513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell 2016, 29: 783–803.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zanconato F, Battilana G, Cordenonsi M, Piccolo S. YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol 2016, 29: 26–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Z, Wang Y, Hu G, Zhou J, Mei L, Xiong WC. YAP is a critical inducer of SOCS3, preventing reactive astrogliosis. Cereb Cortex 2016, 26: 2299–2310.

Article  PubMed  Google Scholar 

Zhao S, Yin J, Zhou L, Yan F, He Q, Huang L, et al. Hippo/MST1 signaling mediates microglial activation following acute cerebral ischemia-reperfusion injury. Brain Behav Immun 2016, 55: 236–248.

Article  CAS  PubMed  Google Scholar 

Qing J, Liu X, Wu Q, Zhou M, Zhang Y, Mazhar M, et al. Hippo/YAP pathway plays a critical role in effect of GDNF against aβ-induced inflammation in microglial cells. DNA Cell Biol 2020, 39: 1064–1071.

Article  CAS  PubMed  Google Scholar 

Xu N, Wu MZ, Deng XT, Ma PC, Li ZH, Liang L, et al. Inhibition of YAP/TAZ activity in spinal cord suppresses neuropathic pain. J Neurosci 2016, 36: 10128–10140.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355: 1432–1444.

Article  CAS  PubMed  Google Scholar 

Wei L, Ma X, Hou Y, Zhao T, Sun R, Qiu C, et al. Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma. Cell Death Discov 2023, 9: 30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen Y, Wang X, Liu Y, Singhal M, Gürkaşlar C, Valls AF, et al. STAT3-YAP/TAZ signaling in endothelial cells promotes tumor angiogenesis. Sci Signal 2021, 14: eabj8393.

Szeto SG, Narimatsu M, Lu M, He X, Sidiqi AM, Tolosa MF, et al. YAP/TAZ are mechanoregulators of TGF-β-smad signaling and renal fibrogenesis. J Am Soc Nephrol 2016, 27: 3117–3128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donohue E, Tovey A, Vogl AW, Arns S, Sternberg E, Young RN, et al. Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem 2011, 286: 7290–7300.

Article  CAS  PubMed  Google Scholar 

Donohue E, Balgi AD, Komatsu M, Roberge M. Induction of covalently crosslinked p62 oligomers with reduced binding to polyubiquitinated proteins by the autophagy inhibitor verteporfin. PLoS One 2014, 9: e114964.

Article  PubMed  PubMed Central  Google Scholar 

Duan B, Cheng L, Bourane S, Britz O, Padilla C, Garcia-Campmany L, et al. Identification of spinal circuits transmitting and gating mechanical pain. Cell 2014, 159: 1417–1432.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 2014, 158: 157–170.

Article  CAS  PubMed  Google Scholar 

Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell 2011, 43: 45–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsutsumi R, Masoudi M, Takahashi A, Fujii Y, Hayashi T, Kikuchi I, et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev Cell 2013, 26: 658–665.

Article  CAS  PubMed